$36.21
3.10% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

IDEAYA Biosciences Inc Stock price

$36.21
+0.21 0.58% 1M
-10.15 21.89% 6M
+0.63 1.77% YTD
+7.90 27.91% 1Y
+11.40 45.95% 3Y
+29.30 424.02% 5Y
+25.02 223.59% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
-1.16 3.10%
ISIN
US45166A1025
Symbol
IDYA
Sector
Industry

Key metrics

Market capitalization $3.06b
Enterprise Value $2.36b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 197.27
P/S ratio (TTM) P/S ratio 255.78
P/B ratio (TTM) P/B ratio 2.96
Revenue growth (TTM) Revenue growth -73.51%
Revenue (TTM) Revenue $11.96m
EBIT (operating result TTM) EBIT $-191.39m
Free Cash Flow (TTM) Free Cash Flow $-134.36m
Cash position $701.66m
EPS (TTM) EPS $-2.18
P/E forward negative
P/S forward 312.75
EV/Sales forward 241.21
Short interest 15.27%
Show more

Is IDEAYA Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

IDEAYA Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a IDEAYA Biosciences Inc forecast:

13x Buy
100%

Analyst Opinions

13 Analysts have issued a IDEAYA Biosciences Inc forecast:

Buy
100%

Financial data from IDEAYA Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
12 12
74% 74%
100%
- Direct Costs 4.19 4.19
22% 22%
35%
7.77 7.77
81% 81%
65%
- Selling and Administrative Expenses 25 25
33% 33%
210%
- Research and Development Expense 170 170
63% 63%
1,420%
-187 -187
130% 130%
-1,565%
- Depreciation and Amortization 4.19 4.19
22% 22%
35%
EBIT (Operating Income) EBIT -191 -191
126% 126%
-1,600%
Net Profit -154 -154
107% 107%
-1,285%

In millions USD.

Don't miss a Thing! We will send you all news about IDEAYA Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

IDEAYA Biosciences Inc Stock News

Neutral
PRNewsWire
9 days ago
SOUTH SAN FRANCISCO, Calif. , Aug. 30, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 29, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 34,000 shares of the Comp...
Neutral
PRNewsWire
13 days ago
SOUTH SAN FRANCISCO, Calif. , Aug. 26, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference.
Neutral
PRNewsWire
16 days ago
SOUTH SAN FRANCISCO, Calif. , Aug. 23, 2024 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on August 19, 2024, the Compensation Committee of IDEAYA's Board of Directors granted non-qualified stock options to purchase an aggregate of 150,000 shares of the Com...
More IDEAYA Biosciences Inc News

Company Profile

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically-defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Head office United States
CEO Yujiro Hata
Employees 124
Founded 2015
Website www.ideayabio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today